A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00952445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.
Study identification
- NCT ID
- NCT00952445
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Not listed
- Completion
- May 31, 2004
- Last update posted
- Oct 18, 2022
2003 – 2004
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Whittier Diabetes Institute | La Jolla | California | — | — |
| Charles R. Drew University | Los Angeles | California | — | — |
| National Research Institute | Los Angeles | California | — | — |
| Lovelace Research Institute | Santa Ana | California | — | — |
| University of Miami | Miami | Florida | — | — |
| GFI Research Center | Evansville | Indiana | — | — |
| Joslin Diabetes Center | Boston | Massachusetts | — | — |
| Radiant Research | Edina | Minnesota | — | — |
| Radiant Research | St Louis | Missouri | — | — |
| St Louis Center for Clinical Research | St Louis | Missouri | — | — |
| Kaleida Health Diabetes Center | Buffalo | New York | — | — |
| Rochester Clinical Research | Rochester | New York | — | — |
| Duke University Medical Center | Durham | North Carolina | — | — |
| Radiant Research | Portland | Oregon | — | — |
| Radiant Research | Anderson | South Carolina | — | — |
| Baylor University Endocrine Center | Dallas | Texas | — | — |
| Dallas Diabetes and Endocrine Research Center | Dallas | Texas | — | — |
| Endocrine Associates of Dallas | Dallas | Texas | — | — |
| Diabetes and Grandular Disease Clinic and Reseach Center | San Antonio | Texas | — | — |
| Endocrine Research Specialists | Ogden | Utah | — | — |
| Salem VA Medical Center | Salem | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00952445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 18, 2022 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00952445 live on ClinicalTrials.gov.